US Stock MarketDetailed Quotes

NAMSW NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)

Watchlist
  • 9.060
  • -0.630-6.50%
Close Nov 29 13:00 ET
9.060High8.290Low
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Comments

    $NewAmsterdam Pharma (NAMS.US)$ ⭕NewAmsterdam Pharma(NAMS)周一表示,对于家族性高胆固醇血症杂合子患者潜在降低胆固醇的药物obicetrapib的3期临床研究已达到主要终点,但是,股价却在消息发布后跌超8%,为此,找到相关本次临床相关信息以便进一步评估其下跌:
    🔺obicetrapib是用于治疗低密度脂蛋白胆固醇(“LDL-C”)升高且有心血管疾病(“CVD”)风险的患者,这些患者现有疗法效果不够好或耐受性不佳
    🔺本次临床试验的对象及其入选条件
    Study Overview
    Brief Summary
    This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hyper...
    ⛔本次下跌合理吗?
    ⛔本次下跌合理吗?
    ⛔本次下跌合理吗?
    +2
Read more